Apr. 15 at 2:06 PM
$IVA @POPEYE832 While I appreciate the logic here of go/no-go for the
$IVA trial, I believe that they will be successful and ultimately take on a massive part of the market. They are the leader in Fibrosis Improvement, which, I believe is the hardest to achieve, most highly sought after liver disease ailment.
Yes, the space has several names, but
$IVA, to date, is statistically the leader.
$MDGL is the clear leader in the space as they were first to market and revenue generating, but I think
$IVA gets a massive portion of the fibrosis market.
Time will tell, but I'm very happy and comfortable with
$IVA.
Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn.
Let's make some (more) money. Cheers!
